NCT02867592 2026-04-13
Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
National Cancer Institute (NCI)
Phase 2 Active not recruiting
Clinical Trials
16 trialsNCT04204850 2025-12-03
Cabozantinib to Treat Recurrent Liver Cancer Post Transplant
University Health Network, Toronto
Phase 2 Recruiting
NCT05168163 2025-09-16
Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer
Academic and Community Cancer Research United
Phase 2 Recruiting
NCT07151326 2025-09-03
CAPIO
National Health Research Institutes, Taiwan
Phase 2 Not yet recruiting
NCT04472767 2025-04-30
Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular Carcinoma
University of California, Irvine
Phase 2 Recruiting
NCT04316182 2025-03-30
ACTION
Fundacion Clinic per a la Recerca Biomédica
Phase 2 Completed
NCT03899428 2025-03-24
Immune Checkpoint Therapy vs Target Therapy in Reducing Serum HBsAg Levels in Patients With HBsAg+ Advanced Stage HCC
Humanity & Health Medical Group Limited
Phase 2 Recruiting
NCT04511455 2025-01-30
Cabozantinib for Patients with Hepatocellular Carcinoma (HCC) Refractory to First Line Treatment
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2 Completed
NCT04522908 2025-01-30
Dose Escalation Study of Cabozantinib for Advanced HCC Patients With Preserved Liver Function
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2 Completed
NCT04767906 2025-01-23
CaPture
University of Leipzig
Phase 2 Completed
NCT06535737 2024-08-02
CPAB
Chulalongkorn University
Phase 2 Not yet recruiting
NCT00940225 2024-04-25
Study of Cabozantinib (XL184) in Adults With Advanced Malignancies
Exelixis
Phase 2 Completed
NCT05039736 2023-05-12
A Phase II Study to Evaluate the Effects of Sequential Therapy With the Anti c-MET/VEGFR Tyrosine Kinase Inhibitor (TKI), Cabozantinib, Followed by an Anti-PD-1 Antibody (Nivolumab) in Patients With Advanced HCC Who Progressed on First-line Therapy
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT05327738 2022-12-14
Yttrium Y 90 Glass Microspheres, Atezolizumab, and Cabozantinib for the Treatment of Unresectable or Locally Advanced Hepatocellular Carcinoma
OHSU Knight Cancer Institute
Phase 2 Withdrawn
NCT04454762 2020-10-05
CaboCHILD
Johannes Gutenberg University Mainz
Phase 2 Unknown
NCT04435977 2020-06-17
Immunocabo
Istituto Clinico Humanitas
Phase 2 Unknown